Skip to content

A study on the efficacy and safety of combined hepatic and renal arterial denervation for the treatment of uncontrolled hypertension

A study on the efficacy and safety of combined hepatic and renal arterial denervation for the treatment of uncontrolled hypertension

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125821
Enrollment
Unknown
Registered
2026-06-01
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uncontrolled hypertension

Interventions

Renal artery sympathetic denervation group:Renal denervation
Hepatic and renal artery combined with sympathetic denervation group:Combined hepatic and renal artery denervation

Sponsors

The First Affiliated Hospital of Chengdu Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged from 18 to 65 years old; 2. Have taken antihypertensive drugs within the past 6 months with uncontrolled blood pressure; 3. Meet the diagnostic criteria of essential hypertension, with office systolic blood pressure >=150 and =90 mmHg, and with uncontrolled blood pressure after standard drug treatment (>=2 antihypertensive drugs used in sufficient doses) for more than 1 month, or unable to tolerate drug treatment; 4. After standard antihypertensive treatment, 24-hour mean ambulatory systolic blood pressure =130mmHg or daytime mean ambulatory systolic blood pressure >=135mmHg; 5. The anatomical structure of common hepatic artery and renal artery was suitable for ablation (vessel diameter 3-8 mm); 6. Clear consciousness, able to cooperate to complete the follow-up and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. History of acute myocardial infarction, acute heart failure, stroke 3 times upper limit of normal, eGFR50%, hepatic artery malformation or severe calcification; 4. Coagulation dysfunction or the use of anticoagulant drugs can not be stopped; 5. Pregnant or lactating women; 6. People with mental disorders or intellectual disabilities who are unable to make independent decisions; 7. Participating in other clinical studies that have not been completed.

Design outcomes

Primary

MeasureTime frame
Office blood pressure;24-hour ambulatory blood pressure;

Secondary

MeasureTime frame
Use of antihypertensive drugs;Kidney function;Liver function ;Heart rate;plasma catecholamine;

Countries

China

Contacts

Public ContactWang Peijian

The First Affiliated Hospital of Chengdu Medical College

wpjmed@aliyun.com+86 189 8071 8263

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026